"text","instanceType","name","description","id","uuid:ID","label"
"To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).","Objective","OBJ1","Main objective","Objective_1","a2fa4d14-f785-430b-99dd-131a49162cb2",""
"To document the safety profile of the xanomeline TTS.","Objective","OBJ2","Safety","Objective_2","cc09a01e-8f4c-45d5-b3db-87615e96a194",""
"To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.","Objective","OBJ3","Behaviour","Objective_3","420588a0-415f-499b-9f0b-1ee95579556e",""
"To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).","Objective","OBJ4","","Objective_4","7303d5d1-c643-4442-9a41-729e60353887",""
"To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).","Objective","OBJ5","","Objective_5","4ad49e85-78a1-4bbe-a7c3-d2298777d01a",""
"To assess the treatment response as a function of Apo E genotype.","Objective","OBJ6","","Objective_6","afd2cdb4-130d-4914-8c50-028a25e20ffa",""
